Fig. 2From: P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signalingDevelopment of OC and tumor size. a Incidence rate (%) of developed OC from 1 to 8 months after DMBA infusion. b The tumor volume (mm3) was measured throughout the experiment. * P < 0.05 vs. the OC group; # P < 0.05 vs. the OC + P-MAPA group. c The tumor mass (g) was recorded at the end of treatments. * P < 0.05 vs. the OC groupBack to article page